A 65-year-old lady presented with worsening peripheral oedema and functional limitation secondary to degeneration of St Jude Epic 21 mm pulmonary and St Jude Epic 27 mm tricuspid valves surgically implanted 4 years previously for carcinoid heart disease. She had maintained NYHA Class I functional capacity until 6 months previously but was now dyspnoeic after walking 100 yards. Echocardiography demonstrated severe pulmonary regurgitation and stenosis, severe tricuspid regurgitation and stenosis, and right ventricular impairment.
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Repeat surgery was considered too high risk, and concomitant transcatheter pulmonary and tricuspid valve-in-valve implantation was planned. Under general anaesthesia and intravenous octeotride cover, the right femoral vein was catheterized and pericardium opened via a left thoracotomy. The patient's existing pacing system was explanted and temporary epicardial pacing established. A 26-French Ascendra sheath was positioned at the right ventricular apex. A balloon-mounted 20-mm Edwards Sapien XT bioprosthetic valve was implanted into the pulmonary position, and a 26-mm Edwards Sapien XT valve was then implanted into the tricuspid position under burst pacing. Transoesophageal echocardiography confirmed successful deployment, with no regurgitation and reduced transvalvular velocities. A transvenous pacing lead was positioned in the coronary sinus, providing ventricular pacing, ventricular sensing, inhibition response, rate-responsive permanent pacing. The patient was discharged after 6 days without complication.
At 6-month follow-up, she is asymptomatic and recently returned from walking in the Alps. To our knowledge, this is the first reported transcatheter, transapical tricuspid, and pulmonary valve-in-valve replacement for bioprosthetic valve degeneration for any condition. This offers an option for high-risk patients requiring repeat surgery in carcinoid disease, where the prognosis is grave. Image focus
